The goal of Benign prostate hyperplasia drugs is to reduce morbidity and prevent complications.Agents used include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase -5 inhibitors and various combinations.
Market Analysis and Insights: Global Benign Prostate Hyperplasia Drugs Market
The global Benign Prostate Hyperplasia Drugs market size is projected to reach US$ million by 2026, from US$ million in 2020, at a CAGR of % during 2021-2026.
Global Benign Prostate Hyperplasia Drugs Scope and Segment
The global Benign Prostate Hyperplasia Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostate Hyperplasia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
By the type, the market is primarily split into
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
By the application, this report covers the following segments
Hospital
Clinic
Other
Competitive Landscape:
The Benign Prostate Hyperplasia Drugs key manufacturers in this market include:
Sanofi
Coloplast
Pfizer
Merck
GlaxoSmithKline
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan
Boehringer Ingelheim
Market Analysis and Insights: Global Benign Prostate Hyperplasia Drugs Market
The global Benign Prostate Hyperplasia Drugs market size is projected to reach US$ million by 2026, from US$ million in 2020, at a CAGR of % during 2021-2026.
Global Benign Prostate Hyperplasia Drugs Scope and Segment
The global Benign Prostate Hyperplasia Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostate Hyperplasia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
By the type, the market is primarily split into
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
By the application, this report covers the following segments
Hospital
Clinic
Other
Competitive Landscape:
The Benign Prostate Hyperplasia Drugs key manufacturers in this market include:
Sanofi
Coloplast
Pfizer
Merck
GlaxoSmithKline
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan
Boehringer Ingelheim
1 Market Overview of Benign Prostate Hyperplasia Drugs
1.1 Benign Prostate Hyperplasia Drugs Market Overview
1.1.1 Benign Prostate Hyperplasia Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Global Benign Prostate Hyperplasia Drugs Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Benign Prostate Hyperplasia Drugs Market Size by Region (2015-2026)
1.4 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Region (2015-2020)
1.5 Global Benign Prostate Hyperplasia Drugs Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.1 North America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.2 Europe Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.3 China Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.5 Latin America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
2 Benign Prostate Hyperplasia Drugs Market Overview by Type
2.1 Global Benign Prostate Hyperplasia Drugs Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Type (2015-2020)
2.3 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2021-2026)
2.4 Alpha Blocker
2.5 5-Alpha Reductase Inhibitor
2.6 Phosphodiesterase-5 Inhibitor
2.7 Others
3 Benign Prostate Hyperplasia Drugs Market Overview by Application
3.1 Global Benign Prostate Hyperplasia Drugs Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Application (2015-2020)
3.3 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinic
3.6 Other
4 Global Benign Prostate Hyperplasia Drugs Competition Analysis by Players
4.1 Global Benign Prostate Hyperplasia Drugs Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2019)
4.3 Date of Key Manufacturers Enter into Benign Prostate Hyperplasia Drugs Market
4.4 Global Top Players Benign Prostate Hyperplasia Drugs Headquarters and Area Served
4.5 Key Players Benign Prostate Hyperplasia Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Benign Prostate Hyperplasia Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Sanofi
5.1.1 Sanofi Profile
5.1.2 Sanofi Main Business and Company’s Total Revenue
5.1.3 Sanofi Products, Services and Solutions
5.1.4 Sanofi Revenue (US$ Million) (2015-2020)
5.1.5 Sanofi Recent Development and Reaction to Covid-19
5.2 Coloplast
5.2.1 Coloplast Profile
5.2.2 Coloplast Main Business and Company’s Total Revenue
5.2.3 Coloplast Products, Services and Solutions
5.2.4 Coloplast Revenue (US$ Million) (2015-2020)
5.2.5 Coloplast Recent Development and Reaction to Covid-19
5.3 Pfizer
5.5.1 Pfizer Profile
5.3.2 Pfizer Main Business and Company’s Total Revenue
5.3.3 Pfizer Products, Services and Solutions
5.3.4 Pfizer Revenue (US$ Million) (2015-2020)
5.3.5 Merck Recent Development and Reaction to Covid-19
5.4 Merck
5.4.1 Merck Profile
5.4.2 Merck Main Business and Company’s Total Revenue
5.4.3 Merck Products, Services and Solutions
5.4.4 Merck Revenue (US$ Million) (2015-2020)
5.4.5 Merck Recent Development and Reaction to Covid-19
5.5 GlaxoSmithKline
5.5.1 GlaxoSmithKline Profile
5.5.2 GlaxoSmithKline Main Business and Company’s Total Revenue
5.5.3 GlaxoSmithKline Products, Services and Solutions
5.5.4 GlaxoSmithKline Revenue (US$ Million) (2015-2020)
5.5.5 GlaxoSmithKline Recent Development and Reaction to Covid-19
5.6 Eli Lilly and Company
5.6.1 Eli Lilly and Company Profile
5.6.2 Eli Lilly and Company Main Business and Company’s Total Revenue
5.6.3 Eli Lilly and Company Products, Services and Solutions
5.6.4 Eli Lilly and Company Revenue (US$ Million) (2015-2020)
5.6.5 Eli Lilly and Company Recent Development and Reaction to Covid-19
5.7 Abbott Laboratories
5.7.1 Abbott Laboratories Profile
5.7.2 Abbott Laboratories Main Business and Company’s Total Revenue
5.7.3 Abbott Laboratories Products, Services and Solutions
5.7.4 Abbott Laboratories Revenue (US$ Million) (2015-2020)
5.7.5 Abbott Laboratories Recent Development and Reaction to Covid-19
5.8 Teva Pharmaceuticals
5.8.1 Teva Pharmaceuticals Profile
5.8.2 Teva Pharmaceuticals Main Business and Company’s Total Revenue
5.8.3 Teva Pharmaceuticals Products, Services and Solutions
5.8.4 Teva Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.8.5 Teva Pharmaceuticals Recent Development and Reaction to Covid-19
5.9 Allergan
5.9.1 Allergan Profile
5.9.2 Allergan Main Business and Company’s Total Revenue
5.9.3 Allergan Products, Services and Solutions
5.9.4 Allergan Revenue (US$ Million) (2015-2020)
5.9.5 Allergan Recent Development and Reaction to Covid-19
5.10 Boehringer Ingelheim
5.10.1 Boehringer Ingelheim Profile
5.10.2 Boehringer Ingelheim Main Business and Company’s Total Revenue
5.10.3 Boehringer Ingelheim Products, Services and Solutions
5.10.4 Boehringer Ingelheim Revenue (US$ Million) (2015-2020)
5.10.5 Boehringer Ingelheim Recent Development and Reaction to Covid-19
6 North America Benign Prostate Hyperplasia Drugs by Players and by Application
6.1 North America Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
6.2 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
7 Europe Benign Prostate Hyperplasia Drugs by Players and by Application
7.1 Europe Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
7.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
8 China Benign Prostate Hyperplasia Drugs by Players and by Application
8.1 China Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
8.2 China Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
9 Rest of Asia Pacific Benign Prostate Hyperplasia Drugs by Players and by Application
9.1 Rest of Asia Pacific Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
10 Latin America Benign Prostate Hyperplasia Drugs by Players and by Application
10.1 Latin America Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
10.2 Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
11 Middle East & Africa Benign Prostate Hyperplasia Drugs by Players and by Application
11.1 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
12 Benign Prostate Hyperplasia Drugs Market Dynamics
12.1 Covid-19 Impact: Industry Trends
12.2 Covid-19 Impact: Market Drivers
12.3 Covid-19 Impact: Market Challenges
12.4 Porter’s Five Forces Analysis
13 Research Finding /Conclusion
14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
1.1 Benign Prostate Hyperplasia Drugs Market Overview
1.1.1 Benign Prostate Hyperplasia Drugs Product Scope
1.1.2 Market Status and Outlook
1.2 Global Benign Prostate Hyperplasia Drugs Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Benign Prostate Hyperplasia Drugs Market Size by Region (2015-2026)
1.4 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Region (2015-2020)
1.5 Global Benign Prostate Hyperplasia Drugs Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.1 North America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.2 Europe Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.3 China Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.5 Latin America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2015-2026)
2 Benign Prostate Hyperplasia Drugs Market Overview by Type
2.1 Global Benign Prostate Hyperplasia Drugs Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Type (2015-2020)
2.3 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2021-2026)
2.4 Alpha Blocker
2.5 5-Alpha Reductase Inhibitor
2.6 Phosphodiesterase-5 Inhibitor
2.7 Others
3 Benign Prostate Hyperplasia Drugs Market Overview by Application
3.1 Global Benign Prostate Hyperplasia Drugs Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Application (2015-2020)
3.3 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinic
3.6 Other
4 Global Benign Prostate Hyperplasia Drugs Competition Analysis by Players
4.1 Global Benign Prostate Hyperplasia Drugs Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2019)
4.3 Date of Key Manufacturers Enter into Benign Prostate Hyperplasia Drugs Market
4.4 Global Top Players Benign Prostate Hyperplasia Drugs Headquarters and Area Served
4.5 Key Players Benign Prostate Hyperplasia Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Benign Prostate Hyperplasia Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Sanofi
5.1.1 Sanofi Profile
5.1.2 Sanofi Main Business and Company’s Total Revenue
5.1.3 Sanofi Products, Services and Solutions
5.1.4 Sanofi Revenue (US$ Million) (2015-2020)
5.1.5 Sanofi Recent Development and Reaction to Covid-19
5.2 Coloplast
5.2.1 Coloplast Profile
5.2.2 Coloplast Main Business and Company’s Total Revenue
5.2.3 Coloplast Products, Services and Solutions
5.2.4 Coloplast Revenue (US$ Million) (2015-2020)
5.2.5 Coloplast Recent Development and Reaction to Covid-19
5.3 Pfizer
5.5.1 Pfizer Profile
5.3.2 Pfizer Main Business and Company’s Total Revenue
5.3.3 Pfizer Products, Services and Solutions
5.3.4 Pfizer Revenue (US$ Million) (2015-2020)
5.3.5 Merck Recent Development and Reaction to Covid-19
5.4 Merck
5.4.1 Merck Profile
5.4.2 Merck Main Business and Company’s Total Revenue
5.4.3 Merck Products, Services and Solutions
5.4.4 Merck Revenue (US$ Million) (2015-2020)
5.4.5 Merck Recent Development and Reaction to Covid-19
5.5 GlaxoSmithKline
5.5.1 GlaxoSmithKline Profile
5.5.2 GlaxoSmithKline Main Business and Company’s Total Revenue
5.5.3 GlaxoSmithKline Products, Services and Solutions
5.5.4 GlaxoSmithKline Revenue (US$ Million) (2015-2020)
5.5.5 GlaxoSmithKline Recent Development and Reaction to Covid-19
5.6 Eli Lilly and Company
5.6.1 Eli Lilly and Company Profile
5.6.2 Eli Lilly and Company Main Business and Company’s Total Revenue
5.6.3 Eli Lilly and Company Products, Services and Solutions
5.6.4 Eli Lilly and Company Revenue (US$ Million) (2015-2020)
5.6.5 Eli Lilly and Company Recent Development and Reaction to Covid-19
5.7 Abbott Laboratories
5.7.1 Abbott Laboratories Profile
5.7.2 Abbott Laboratories Main Business and Company’s Total Revenue
5.7.3 Abbott Laboratories Products, Services and Solutions
5.7.4 Abbott Laboratories Revenue (US$ Million) (2015-2020)
5.7.5 Abbott Laboratories Recent Development and Reaction to Covid-19
5.8 Teva Pharmaceuticals
5.8.1 Teva Pharmaceuticals Profile
5.8.2 Teva Pharmaceuticals Main Business and Company’s Total Revenue
5.8.3 Teva Pharmaceuticals Products, Services and Solutions
5.8.4 Teva Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.8.5 Teva Pharmaceuticals Recent Development and Reaction to Covid-19
5.9 Allergan
5.9.1 Allergan Profile
5.9.2 Allergan Main Business and Company’s Total Revenue
5.9.3 Allergan Products, Services and Solutions
5.9.4 Allergan Revenue (US$ Million) (2015-2020)
5.9.5 Allergan Recent Development and Reaction to Covid-19
5.10 Boehringer Ingelheim
5.10.1 Boehringer Ingelheim Profile
5.10.2 Boehringer Ingelheim Main Business and Company’s Total Revenue
5.10.3 Boehringer Ingelheim Products, Services and Solutions
5.10.4 Boehringer Ingelheim Revenue (US$ Million) (2015-2020)
5.10.5 Boehringer Ingelheim Recent Development and Reaction to Covid-19
6 North America Benign Prostate Hyperplasia Drugs by Players and by Application
6.1 North America Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
6.2 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
7 Europe Benign Prostate Hyperplasia Drugs by Players and by Application
7.1 Europe Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
7.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
8 China Benign Prostate Hyperplasia Drugs by Players and by Application
8.1 China Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
8.2 China Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
9 Rest of Asia Pacific Benign Prostate Hyperplasia Drugs by Players and by Application
9.1 Rest of Asia Pacific Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
10 Latin America Benign Prostate Hyperplasia Drugs by Players and by Application
10.1 Latin America Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
10.2 Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
11 Middle East & Africa Benign Prostate Hyperplasia Drugs by Players and by Application
11.1 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Application (2015-2020)
12 Benign Prostate Hyperplasia Drugs Market Dynamics
12.1 Covid-19 Impact: Industry Trends
12.2 Covid-19 Impact: Market Drivers
12.3 Covid-19 Impact: Market Challenges
12.4 Porter’s Five Forces Analysis
13 Research Finding /Conclusion
14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
